<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02681419</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-12-0800</org_study_id>
    <nct_id>NCT02681419</nct_id>
  </id_info>
  <brief_title>Evaluating the Efficacy of Fenestrations in Tube Shunt Implants During the Early Postoperative Period</brief_title>
  <official_title>Evaluating the Efficacy of Fenestrations in Tube Shunt Implants During the Early Postoperative Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Robert Cizik Eye Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates two different methods of controlling intraocular pressure in nonvalved
      aqueous tube shunts immediately after implantation; needle fenestrations or a suture wick.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized control study of glaucomatous eye undergoing tube shunt
      implantation using a nonvalved implant for poorly controlled glaucoma of any type. Eyes
      scheduled to receive a nonvalved tube shunt implant will be randomized to receive either
      needle fenestration(s) or a suture wick using a single 10-0 vicryl anterior to the ligature.
      The operative quadrant will be imaged using anterior-segment optical coherence tomography at
      pre- and post-operative visits.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigator left institution
  </why_stopped>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 17, 2017</completion_date>
  <primary_completion_date type="Actual">March 17, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with successful control of intraocular pressure</measure>
    <time_frame>3 weeks</time_frame>
    <description>Successful control of intraocular pressure is defined as IOP between 5 and 21 mmHg without medications within 3 weeks postop.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of effect on intraocular pressure control</measure>
    <time_frame>12 weeks</time_frame>
    <description>The duration of effect is defined as elapsed time from surgery to the time that intraocular pressure (IOP) &gt;5 mmHg or &lt;21 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-fenestration bleb volume prior to tube opening</measure>
    <time_frame>3 weeks</time_frame>
    <description>Bleb volume will be measured by the anterior segment optical coherence tomography (ASOCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-fenestration bleb volume after the tube has opened</measure>
    <time_frame>12 weeks</time_frame>
    <description>Bleb volume will be measured by the anterior segment optical coherence tomography (ASOCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure after the tube has opened</measure>
    <time_frame>12 weeks</time_frame>
    <description>Successful control of intraocular pressure is defined as IOP between 5 and 21 mmHg without medications at 12 weeks postop</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Needle fenestration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Needle fenestration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suture wick</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>suture wick using 10-0 vicryl</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Needle fenestration</intervention_name>
    <description>This technique creates fenestrations along a nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature</description>
    <arm_group_label>Needle fenestration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Suture wick</intervention_name>
    <description>This technique places a single 10-vicryl suture wick through the nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature</description>
    <arm_group_label>Suture wick</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Eyes that have poorly controlled glaucoma requiring a tube shunt implantation

          -  Willingness to participate in the study and sign informed consent

        Exclusion Criteria:

          -  Concurrent surgery except phaco/intraocular lens

          -  Any abnormality preventing reliable applanation tonometry

          -  Eyes with exposure limitation (tight lids, deep orbits) that would make performing the
             anterior segment optical coherence tomography difficult
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauren S. Blieden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robert Cizik Eye Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert Cizik Eye Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2016</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Robert Feldman</investigator_full_name>
    <investigator_title>Department Chair</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

